S
everal recent clinical trials for high-grade gliomas have demonstrated promising results. Nonetheless, despite improvement in survival, these patients ultimately die of tumor progression. Malignant glioma patients are profoundly immunosuppressed, and a fundamental understanding of which types of glioma have immune resistance mediated by Tregs is required for developing and initiating specific immunotherapeutic approaches that may target these cells.
Tregs Incidence and Frequency in Gliomas
Immune cell infiltrates are present in human gliomas, and previous studies have attempted to correlate the number of tumor-infiltrating immune cells with a positive prognosis; however, the findings of these studies have not been definitive. 5, 46, 50, 51 This lack of correlation between the presence of effector T cells (CD4 ϩ or CD8 ϩ ) in gliomas and improved survival is likely secondary to these analyses not accounting for the immunosuppressive cell populations such as Tregs and the lack thereof of functional activity in the infiltrating effector immune population. 27 This current study was an attempt to account for the confounding factor of the immunoinhibitory Tregs in this type of analysis. FoxP3 ϩ Tregs (CD3 ϩ CD4 ϩ CD25 ϩ FoxP3 ϩ ) are inhibitors of antitumor immunity and have been shown to be present in the blood and malignant effusions of patients with cancer. 7, 39, 42, 44, 52 In glioblastoma multiforme (GBM) patients, there is an increased number of Tregs in peripheral blood relative to the CD4 ϩ T cells, and this directly correlates with the impairment of CD4 ϩ T-cell proliferation. 10 Tregs are also present in the GBM microenvironment, 3, 27 likely secondary to gliomas elaborating CCL-2, a Treg chemokine CCL2. 29 In many systemic, non-central nervous system (CNS) cancers, the presence of Tregs in the tumor is an unfavorable prognostic marker 14, 24, 32 ; however, this is not universally seen in all malignancies. 17 The prognostic role of Tregs present in gliomas has not been previously evaluated, and therefore we determined the incidence and prognostic significance of FoxP3 22 also contained normal brain tissue (white matter, cortex, and cerebellum) and was stained for CD3, CD4, CD8, and FoxP3 (Dr. Nobuyoshi Hiraoka) as previously described. 23, 24 The number of infiltrating immune cells was determined in duplicate from different areas of the same tumor by four independent observers in a blinded fashion. The duplicate specimens from each tumor were then averaged to calculate the final number of CD3 ϩ , CD4 ϩ , CD8 ϩ , and FoxP3 ϩ lymphocytes per surgical specimen. An equal-proportion examination with respect to tumor grade, pathological type, and glial lineage (astrocytic versus oligodendroglial) was conducted. 49 Kaplan-Meier product-limit probability estimates of overall survival (OS) were calculated, 30 and log-rank tests 40 were performed to compare OS according to FoxP3 positivity (versus FoxP3 negativity), tumor grade, astrocytic, and oligodendroglial lineage, and sex. In each fitted OS regression model, nonsignificant variables were eliminated in a step-down fashion using a P value cutoff of 0.10. Comparisons of infiltrating immune populations were performed using t tests, assuming unequal variances with statistical significance set at 0.05.
In the 135 study patients, parameters such as age and Karnofsky Performance Scale were similar to those of patients in previous studies that examined prognostic markers in glioma patients. 4, 21, 22 Of the GBM patients, nine (17%) had received previous chemotherapy and 11 (21%) had received previous radiation therapy. Figure 18 .1 demonstrates the immunohistochemistry staining of the infiltrating immune populations. A CD8 ϩ cell population was identified in the majority of the glioma specimens regardless the grade (Fig. 18.2A) ; however, the number of patients who had a CD4 ϩ population present increased with tumor grade from 39% (7/18) ϩ T cells in all glioma grades. All images were taken at ϫ400. Oligodendroglioma (a), mixed oligoastrocytoma (b), anaplastic oligodendroglioma (c), anaplastic mixed oligodendroglioma (d), low-grade astrocytoma (e), anaplastic astrocytoma (f), glioblastoma (g) and gliosarcoma (h). different from that in patients with anaplastic astrocytoma, the number of FoxP3 ϩ Tregs present in the tumor of GBM patients (at least 5 per core; 7 ͓14%͔) was markedly higher than that in the anaplastic astrocytoma patients. Thus, as the glioma grade increased, the number of cells that stained positively for FoxP3 increased (P ϭ 0.008) ( Table 18. 3); this increase was even more pronounced in tumors of astrocytic lineage than in those of oligodendroglial lineage. These data are consistent with the findings of a previous study demonstrating that number of FoxP3 ϩ T cells increased in astrocytic glioma grade. 9
Influence of Tregs on Survival in Glioma Patients
Because the presence of FoxP3 ϩ Tregs correlated with the overall malignant behavior of astrocytic tumors, we next determined whether the presence of FoxP3 ϩ Tregs was a prognosticator of survival in glioma pathologies. The median survival duration in patients with GBM who had intratumoral FoxP3 ϩ Tregs was 13.8 months (95% confidence interval ͓CI͔, 7.8 -21.7), and in patients with GBM who did not have any intratumoral FoxP3 ϩ Tregs, it was 12.8 months (95% CI, 6.6 -37.7) (P ϭ 0.56) ( Fig. 18.3) . Although there was a trend of a higher probability of survival at 2 years in patients who did not have FoxP3 ϩ Tregs (0.32; 95% CI, 0.18 -0.57) ϩ cells were identified in the majority of the glioma specimens despite the grade; however, the number of patients who had a CD4 ϩ population present increased with tumor grade (P Ͻ 0.001; across all grades). B, The number of both CD4 ϩ and CD8 ϩ glioma infiltrating T cells increased with tumor grade. ϩ Tregs in these tumors. A hypothesized parameter that may be more predictive of prognosis than solely the presence of Tregs is the balance between cytotoxic and regulatory T cells (i.e., the effectorto-suppressor ratio). Other investigators 2, 14, 47 reported that this ratio is more valuable for prognostic purposes than the presence of a single tumor-infiltrating lymphocyte subset. We also analyzed the data set based on the ratio of FoxP3 ϩ Tregs (immune inhibitors) to CD8 ϩ T cells (cytotoxic effector) to determine whether the relative balance of these factors influences prognosis. Within the GBM group, we found that this ratio did not have a significant prognostic effect (P ϭ 0.17; hazard ratio, 1.04; 95% CI, 0.98 -1.10). This lack of prognostic influence is likely secondary to multiple redundant immunosuppressive mechanisms in the glioma patients. Although some cancers may mediate immunosuppression predominantly by using Tregs, researchers have shown that high-grade gliomas have multiple mechanisms for mediating immunosuppression 8 ; thus, the lack of a prognostic impact of a single mechanism of immune suppression such as the presence or absence of FoxP3 ϩ Tregs in this setting is not entirely surprising. Furthermore, the ratio of FoxP3 ϩ Tregs to CD8
ϩ T-cell effectors may not be valid as a prognosticator in gliomas because the effector cells in gliomas are not activated 27 and likely are not functional. 41, 43 A further limitation of this study is that we are only determining the influence of Tregs within the tumor microenvironment and have not ϩ immunohistochemical staining in glioblastoma multiforme (GBM) patients. Median survival in GBM patients who had FoxP3 ϩ staining was 13.8 (95% confidence interval ͓CI͔, 7.8 -21.7) months and was 12.8 (95% CI, 6.6 -37.7) months in GBM patients who did not have FoxP3 staining, which is not statistically significant (P ϭ 0.56). 
Inhibition of Tregs With STAT3 Blockade
Although the presence of Tregs was not an independent prognostic factor for survival in glioma patients, their influence on restraining antiglioma immune responses has been clearly established. 10, 11, 12 In a study of a syngeneic murine model of glioma, in vivo depletions of Tregs resulted in complete tumor rejection and markedly enhanced survival. 10 A variety of approaches to negating the negative immunomodulatory properties of Tregs in patients with glioma are being considered for clinical trials, including treatment with CTLA-4 blockade that confers resistance to Treg-mediated suppression, 11 an anti-CD25 antibody that binds to the surface of Tregs and disrupts their functional activity, 12 cyclophosphamide that selectively depletes the number of Tregs, 15, 16 and temozolomide that inhibits Treg trafficking to the glioma. 29 Some of these aforementioned agents have already been used in clinical trials of patients with systemic cancers with notable progression of disease occurring in CNS. 45 The variability of the infiltrating Treg population within tumors and the systemic circulation 10 suggests that not all patients will uniformly benefit from these approaches and that the greatest clinical responses to these agents may be seen in patients with significant tumor Treg infiltration and/or an enhanced Treg fraction in a diminished CD4 compartment in the systemic circulation.
The Janus kinases/signal transducers and activators of transcription 3 (JAK/STAT3) pathway is a key signaling pathway that drives the fundamental components of tumorigenesis 37, 53, 54 and transduces extracellular signals such as the epidermal growth factor receptor (EGFR) and interleukin-6, which is expressed in the CNS. The STAT3 protein is overexpressed in most cancers, including gliomas, 1 and fosters tumorigenesis by preventing apoptosis and enhancing proliferation, angiogenesis, and invasiveness 25, 53 and is a key regulator of immunosuppression in cancer patients. 36, 54 Previous studies in mice have shown that the ablation of STAT3 in the hematopoietic system was accompanied by a reduction in the number of tumor-infiltrating Tregs. 36 STAT3 has also been shown to be required for both transforming growth factor ␤ and interleukin-10 production by CD4 ϩ T cells, 31 factors necessary for the generation of tumor-associated Tregs. Interleukin-2 has been shown to regulate FoxP3 expression in human CD4 ϩ CD25 ϩ Tregs by STAT3 binding of the first intron of the FoxP3 gene. 55 Thus, blockade of the STAT3 pathway should theoretically potently inhibit Tregs and reverse immunosuppression while exerting a direct antitumor effect, the latter of which is a property that the other previously mentioned Treg inhibitory agents either lack or is minimal.
WP1066, a novel low molecular weight agent, has been shown to effectively block the JAK2/STAT3 pathway 6, 13, 18, 28, 34, 38 and can inhibit glioma (U-87) growth in vivo. 28 WP1066 can penetrate the CNS in mice and, in physiologically relevant doses in vitro, reverse tolerance in immune cells isolated from GBM patients. 26 WP1066 activates the immune system by inducing expression of costimulatory molecules, stimulating the production of the immunostimulatory cytokines, and inducing T-cell effector responses, even in cancer patients who are refractory to CD3 stimulation. 26 To evaluate whether WP1066 could improve survival in mice, C57BL/6J mice with intracerebral B16EGFRvIII were treated by oral gavage with WP1066 starting on day 3 after tumor cell implantation. Kaplan-Meier product-limit survival probability estimates of OS were calculated 30 and log-rank tests 40 were performed to compare OS between treatment groups and the control arm. A P value of Յ0.05 was considered statistically significant. The median survival time for the control group was 17.5 days (95% CI, 16 to not available). For the mice treated by oral gavage with WP1066 at 40 mg/kg (n ϭ 10), 80% survived long term (Ͼ78 days) (P Ͻ 0.0001 compared with the control group), and there was at least a 324% increase in median survival time when the experiment was terminated to perform tumor rechallenge experiments (Fig. 18.4A) .
To determine whether mice with intracerebral tumors treated with WP1066 were able to generate long-lasting protection against tumor regrowth, mice that survived for 78 days after the initial tumor cell implantation were reinoculated with B16EGFRvIII cells, but in the contralateral hemisphere. On this rechallenge, in the animal group that had received WP1066 by oral gavage, the median survival time was 18 days (95% CI, 17 to not available), which was significantly different from 11 days, the median survival time of naïve animals challenged at the same time (95% CI, 10 to not available; P Ͻ 0.001); however, only 10% of the mice were long-term survivors (Fig. 18.4A) . The longer median survival time compared with naïve control animals demonstrates a partial protective immune effect, yet, ultimately, these mice were not long-term survivors, indicating that maintenance of the immune effects of WP1066 will require sustained dosing if a tumor recurs.
To further clarify that the immune system is the primary mediator of the in vivo efficacy in the CNS, we implanted the B16EGFRvIII tumors in the CNS of nude animals and then treated with WP1066. In contrast, to our previous findings in which WP1066 resulted in marked longterm survival, in nude mice that had established intracerebral B16EGFRvIII, there was no enhancement of long-term survival with WP1066, and all animals died of progressive tumor in the CNS (Fig. 18.4B) . Furthermore, in the syngeneic murine model when we performed in vivo depletions of the CD4 and CD8 T cell population (Fig. 18.4C ), therapeutic efficacy were lost. However, in vivo depletion of natural killer cells demonstrated no loss in therapeutic efficacy, suggesting that the tumor cytolytic mechanism may to be a major histocompatibility complex-restricted CD8 ϩ T cellmediated cytolysis. Cumulatively, these data indicate that the immune system contributes to the clearance of CNS tumors with anti-STAT3 agents.
The underlying mechanism of WP1066-mediated CNS immune clearance of gliomas was further assessed by evaluating whether WP1066 could enhance humoral responses. C57BL/6J mice were vaccinated with phosphate-buffered saline (PBS), WP1066, PEP-3-KLH/CDX-110 (a 14-mer peptide spanning the epidermal growth factor variant III (EGFRvIII) that is currently in phase II testing for GBM patients; www.celldextherapeutics.com), PEP-3-KLH ϩ WP1066, and PEP-3-KLH ϩ complete Freund's adjuvant (positive control) and evaluated for humoral responses after the first and third vaccinations as described. 48 None of the animals treated with PBS (n ϭ 3), PEP-3-KLH (n ϭ 3), or PEP-3-KLH ϩ complete Freund's adjuvant (n ϭ 3) had detectable humoral responses to EGFRvIII after the first vaccination. EGFRvIII humoral responses were not detected in the mice that were vaccinated 3 times with PBS (n ϭ 5), PEP-3-KLH (n ϭ 5), or WP1066 alone (n ϭ 4). As expected, mice that were vaccinated three times with PEP-3-KLH ϩ complete Freund's adjuvant all (n ϭ 5) produced significant quantities of immunoglobulin G antibody, ranging from 1,156 to 10,308 ng/mL. In contrast, mice treated with the combination of PEP-3-KLH ϩ WP1066 (n ϭ 5) showed no detectable EGFRvIII antibody responses (Fig. 18.5A) . Furthermore, in animals (n ϭ 8) that survived intracerebral tumor treatment with WP1066 ( Fig. 18.4A) ; none demonstrated the induction of EGFRvIII-specific responses, indicating that WP1066 does not appear to exert antiglioma activity by EGFRvIII antibody responses.
However, WP1066 significantly enhanced cytotoxic responses directed against PEP-3. Splenocytes from naïve C57BL/6J mice and C57BL/6J mice vaccinated with PEP-3-KLH, WP1066, PEP-3-KLH ϩ WP1066, and PEP-3-KLH ϩ complete Freund's adjuvant were stimulated in vitro with FIGURE 18.4. Survival data from C57BL/6J mice treated with WP1066 (WP) after intracerebral B16EGFRvIII cells were established in the brain. A, C57BL/6J mice with established intracerebral B16EGFRvIII cells treated with WP1066 via oral gavage (og) (n ϭ 10) showed at least a 324% increase in their median survival time, and 80% achieved long-term survival compared with the vehicle-treated controls (n ϭ 10). For the group treated with 40 mg/kg WP1066 by oral gavage, the P values were 0.04, 0.18, 0.007, 0.002, 0.001, and 0.001 at days 25, 30, 35, 40, 45 , and 50, respectively, compared with the vehicle control group. In animals that survived longer than 78 days, subsequent rechallenge by injection of tumor cells into the contralateral hemisphere indicated that minimal immunological memory was induced. B, The therapeutic effect of WP1066 was lost when WP1066 was used to treat established B16EGFRvIII tumors in immunoincompetent nude mice. C, Monoclonal antibodies GK1.5 (anti-CD4 ϩ ), 2.43 (anti-CD8 ϩ ), and polyclonal anti-asialo GM1 (anti-natural killer) were injected once intravenously 3 days before tumor challenge and intraperitoneally every 5 days thereafter with pretitrated amounts of the antibody. The efficacy of WP1066 in suppressing intracerebral tumor was abrogated when CD4 ϩ or CD8 ϩ T cells were depleted. The experiment was terminated on day 35. NK, natural killer.
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Tregs in Gliomas B16EGFRvIII cells, and cytotoxicity was assessed against carboxyfluorescein succinimidyl ester-labeled B16EGFRvIII target cells. The naïve mice showed minimal lysis of the B16EGFRvIII target cells. The PEP-3-KLH-or WP1066-treated mice had increased cytotoxic clearance of the B16EGFRvIII target cells compared with naïve mice (Fig.  18 .5B). In mice treated with both PEP-3-KLH-and WP1066, there was further significant enhanced cytotoxic clearance of the B16EGFRvIII target cells compared with mice that were treated with either WP1066 or PEP-3-KLH alone (P Ͻ 0.05; Fig. 18 .5B) indicating that WP1066 enhances direct tumor clearance. Finally, to investigate the effects of WP1066 on the peripheral induction of FoxP3 ϩ Tregs, we used an in vitro Treg induction system in which FoxP3 expression was induced in naïve CD4 ϩ (CD4 ϩ CD25-CD62L hi ) T cells isolated from the spleens of C57BL/6J mice. 33, 35 FoxP3 ϩ Treg generation was directly measured by intracellular staining for ϩ CD25-CD62Lhi naïve T cells from C57BL/6J mice were stimulated by plate-bound anti-CD3 (2 g/mL) and soluble anti-CD28 (2 g/mL) in the presence of transforming growth factor ␤ 1 (1 ng/mL) and interleukin-2 (200 U/mL) with 0, 0.1, and 1.0 M WP1066 for inducible Tregs (iTreg) differentiation; CD4 ϩ CD25 ϩ T cells (natural Tregs, nTreg) were stimulated by plate-bound anti-CD3 (2 g/mL) and soluble anti-CD28 (2 g/mL) in the presence of interleukin-2 (200 U/mL) with 0, 0.1, and 1.0 M WP1066. Ninety-six hours after stimulation, the cells were analyzed for intracellular FoxP3 expression by flow cytometry. The percentage numbers for the indicated population are shown.
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ϩ Treg differentiation when they were activated by polyclonal stimulation in the presence of exogenous transforming growth factor-␤. In contrast, WP1066 inhibited FoxP3 ϩ Treg induction, compared with the control, from 70% to 54% with WP1066 ( Fig. 19.5C ). Moreover, WP1066 reduced Foxp3 ϩ natural Tregs (nTregs) to 13.8% under polyclonal stimulation (Fig. 5C) . We also recently showed that WP1066 enhances CD3 ϩ (which contain Tregs) T cell-mediated tumor cytotoxicity but fails to do so when the Tregs were excluded, indicating that WP1066 does not primarily activate T-cell responses but secondarily via inhibition of Tregs. 33 In conclusion, WP1066 appears to inhibit the induction of Tregs, which contributes to the antitumor responses observed with its use in vivo.
Implications for Therapeutics
Patients with advanced malignancies are known to be profoundly immunosuppressed and even if a systemic immune response can be generated, it is likely negated in the tumor microenvironment by a wide variety of factors including Tregs. 9,10,27 STAT3 blockade appears to be a highly promising therapeutic approach given the ability of WP1066 to inhibit Tregs, reverse immunosuppression, and favorably modulate the tumor microenvironment. WP1066 could potentially be used in combination with other immunotherapeutic approaches such as dendritic cells, 19 peptide vaccination, 20 and cytokine immunotherapy or adoptive immunotherapy. In addition to immunomodulatory properties, WP1066 also acts directly on the process of tumorigenesis by inhibiting the phosphorylation of STAT3 and the subsequent downstream molecules, such as survivin and c-Myc. Given its oral bioavailability, inherent immunomodulatory properties, direct tumor cytotoxicity activity, ability to enter the CNS, and efficacy against established CNS tumors, WP1066 is a compelling agent for further development and translation to applications for patients with gliomas.
